New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:15 EDTARRY, CGIX, EXEL, GILD, MNK, QSII, AHS, SGENUBS to hold a conference
2014 Global Healthcare Conference to be held in New York on May 19-21 with webcasted company presentations to begin on May 20 at 8 am; not all company presentations may be webcasted. Webcast Link
News For ARRY;CGIX;EXEL;GILD;MNK;QSII;AHS;SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 25, 2014
08:42 EDTGILDGilead price target raised to $130 from $120 at Bernstein
Subscribe for More Information
08:27 EDTGILDGilead viral suppression data for TAF better than expected, says UBS
UBS said the viral suppression data reported by Gilead from two studies of tenofovir alafenamide, or TAF, in HIV-1 treatment was better than expected and the firm expects the results to have a positive impact on adoption. The firm maintains its Buy rating and $125 price target on Gilead.
September 24, 2014
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
09:28 EDTGILDGilead price target raised to $118 from $111 at Piper Jaffray
Subscribe for More Information
09:07 EDTSGENSeattle Genetics reports additional data from Phase 1 trial of ADCETRIS
Subscribe for More Information
09:06 EDTCGIXCancer Genetics to host analyst day
Analyst Day to be held in Raleigh, North Carolina on September 25 at 10 am. Webcast Link
08:39 EDTGILDGilead's two TAF Phase 3 trials meet primary objectives
Subscribe for More Information
05:12 EDTGILDGilead submits NDA to Japan for fixed-dose combination of Ledipasvir/Sofosbuvir
Gilead Sciences announced that the company has submitted a New Drug Application, or NDA, to Japanís Pharmaceutical and Medical Devices Agency, or PMDA, for approval of an investigational once-daily fixed-dose combination of the NS5A inhibitor ledipasvir, or LDV, 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, 400 mg for the treatment of chronic genotype 1 hepatitis C virus, or HCV, infection in adults. The data submitted in the NDA, which include a Japanese Phase 3 study showing 100 percent SVR12 rates, support the use of LDV/SOF for 12 weeks in treatment-naÔve and treatment-experienced patients with chronic genotype 1 HCV infection, including those with cirrhosis. Patients who achieve SVR12 are cured of HCV infection. If approved, LDV/SOF would simplify HCV treatment for genotype 1 patients in Japan to one daily tablet, eliminating the need for interferon and ribavirin, or RBV. LDV/SOF is currently under regulatory review in the United States and European Union.
September 23, 2014
09:54 EDTARRYArray BioPharma management to meet with Jefferies
Subscribe for More Information
08:07 EDTGILDFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
07:57 EDTCGIXCancer Genetics and Beth Israel Deaconess enter into collaboration
Subscribe for More Information
September 22, 2014
10:16 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:15 EDTGILDIntercept recent weakness a buying opportunity, says Summer Street
Subscribe for More Information
05:49 EDTMNKMallinckrodt reinstated with an Overweight at Barclays
Subscribe for More Information
September 19, 2014
11:26 EDTGILDStocks with call strike movement; TSLA GILD
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
06:25 EDTGILDGilead granted marketing aurhotization from European Commission for Zydelig
Subscribe for More Information
06:11 EDTGILDGilead price target raised to $139 from $111 at Citigroup
Citigroup raised its price target for Gilead shares to $139 saying management looks "very optimistic" that FY15 hepatitis C treatment volumes could be up substantially over FY14 rates globally. Citi also expects recent buybacks to boost Q4 earnings substantially and that future stock buybacks will drive appreciation. The firm keeps a Buy rating on Gilead.
September 18, 2014
12:12 EDTGILDStocks with call strike movement; PIR GILD
Subscribe for More Information
08:17 EDTGILDGilead trial failure not material, says FBR Capital
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use